Regeneron Faces Setback After Court Ruling on Eylea Biosimilar

1 min read | September 24, 2024 12:14 PM PDT | By Team Kalkine Media

Headlines

  • Regeneron Pharmaceuticals' shares fell by 4.63% following a court ruling.
  • The decision involved a legal dispute with Amgen regarding the biosimilar of Eylea.
  • The outcome may influence Regeneron's market position and future developments.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)experienced a decline of 4.63% in its stock value after a court ruling impacted its lawsuit against Amgen AMGN. The case, decided in the United States District Court for the Northern District of West Virginia, centered around Amgen's biosimilar of Eylea. This development could affect Regeneron's competitive standing and future market dynamics.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.


Sponsored Articles


Investing Ideas

Previous Next